Haemonetics/$HAE
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Haemonetics
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Ticker
$HAE
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
3,023
ISIN
US4050241003
Website
Haemonetics Metrics
BasicAdvanced
$3.7B
23.22
$3.31
0.37
-
Price and volume
Market cap
$3.7B
Beta
0.37
52-week high
$93.22
52-week low
$55.30
Average daily volume
531K
Financial strength
Current ratio
1.617
Quick ratio
0.881
Long term debt to equity
112.231
Total debt to equity
156.347
Interest coverage (TTM)
6.88%
Profitability
EBITDA (TTM)
349.564
Gross margin (TTM)
57.21%
Net profit margin (TTM)
12.32%
Operating margin (TTM)
18.16%
Effective tax rate (TTM)
20.93%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
6.29%
Return on equity (TTM)
18.83%
Valuation
Price to earnings (TTM)
23.224
Price to revenue (TTM)
2.843
Price to book
4.52
Price to tangible book (TTM)
-15.81
Price to free cash flow (TTM)
27.16
Free cash flow yield (TTM)
3.68%
Free cash flow per share (TTM)
283.03%
Growth
Revenue change (TTM)
3.95%
Earnings per share change (TTM)
44.54%
3-year revenue growth (CAGR)
11.07%
10-year revenue growth (CAGR)
4.10%
3-year earnings per share growth (CAGR)
57.95%
10-year earnings per share growth (CAGR)
26.32%
What the Analysts think about Haemonetics
Analyst ratings (Buy, Hold, Sell) for Haemonetics stock.
Bulls say / Bears say
Needham upgraded Haemonetics to a Buy rating with a price target of $112, citing confidence in the company's ability to achieve its 'high-20%' operating margin target for fiscal year 2026. (Investing.com)
Haemonetics reported a 7% increase in Q2 2024 revenue to $318 million, indicating positive growth momentum. (Yahoo Finance)
The company targets 24% to 26% hospital revenue growth, driven by momentum in hemostasis and vascular closure products. (Seeking Alpha)
Haemonetics missed Q4 revenue estimates, reporting $348.5 million against analyst expectations of $353 million, raising concerns about meeting future targets. (ChartMill)
BofA Securities initiated coverage with a Neutral rating, noting that margin expectations for fiscal years 2025 and 2026 may be too optimistic, requiring outperformance for stock re-rating. (Investing.com)
Analysts from firms like Raymond James, Mizuho, Barrington, JMP Securities, and BofA have reduced their price targets for Haemonetics following mixed Q3 earnings and lowered fiscal year 2025 growth guidance. (TipRanks)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Haemonetics Financial Performance
Revenues and expenses
Haemonetics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Haemonetics stock?
Haemonetics (HAE) has a market cap of $3.7B as of July 04, 2025.
What is the P/E ratio for Haemonetics stock?
The price to earnings (P/E) ratio for Haemonetics (HAE) stock is 23.22 as of July 04, 2025.
Does Haemonetics stock pay dividends?
No, Haemonetics (HAE) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Haemonetics dividend payment date?
Haemonetics (HAE) stock does not pay dividends to its shareholders.
What is the beta indicator for Haemonetics?
Haemonetics (HAE) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.